DiaSorin S.p.A.

Milan Stock Exchange:DIA.MI

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

🩺 Medical Instruments

💻 Telehealth

Location

Italy

Market Cap

USD 5.83 B

Share Price

USD 107.84

Avg Daily Volume

152,641

Change (1 day)

-1.95%

Change (1 year)

7.78%

Change (YTD)

4.08%

DiaSorin S.p.A. Revenue Per Share for the year ending December 31, 2024: USD 21.96

DiaSorin S.p.A. Revenue Per Share is USD 21.96 for the year ending December 31, 2024, a -3.39% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.

DiaSorin S.p.A. Revenue Per Share for the year ending December 31, 2023 was USD 22.73, a -9.85% change year over year.
DiaSorin S.p.A. Revenue Per Share for the year ending December 31, 2022 was USD 25.22, a 2.24% change year over year.
DiaSorin S.p.A. Revenue Per Share for the year ending December 31, 2021 was USD 24.67, a 25.46% change year over year.
DiaSorin S.p.A. Revenue Per Share for the year ending December 31, 2020 was USD 19.66, a 35.71% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue Per Share	Free Cash Flow Per Share	Dividend Per Share	Debt to Equity Ratio

Milan Stock Exchange: DIA.MI

DiaSorin S.p.A.

CEO	Mr. Carlo Rosa
IPO Date	July 19, 2007
Location	Italy
Headquarters	Via Crescentino snc
Employees	3,249
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 🩺 Medical Instruments 💻 Telehealth

Description

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform comprising of LIAISON MDX for use in the amplification of nucleic acids to diagnose viral infections through the identification of virus in patient's biological sample. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.